Salvage therapy for multidrug-resistant tuberculosis

Clinical Microbiology and Infection

Volumn 20, Issue 5, 2014, Pages 441-446

  Seung, K J ^a,b   Becerra, M C ^a,b,c   Atwood, S S ^a   Alcantara F ^b   Bonilla, C A ^d   Mitnick, C D ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PARTNERS IN HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HOSPITAL NACIONAL DANIEL ALCIDES CARRIÓN   (Peru)

Author keywords

Culture conversion; Moxifloxacin; Multidrug resistant tuberculosis; Peru

Indexed keywords

AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; QUINOLONE DERIVATIVE;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM CULTURE; CROSS RESISTANCE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PATIENT MONITORING; PERU; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SPUTUM CULTURE; TREATMENT DURATION; DRUG COMBINATION; DRUG EFFECTS; MICROBIOLOGY; PROCEDURES; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

MYCOBACTERIUM TUBERCULOSIS;

ADULT; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTITUBERCULAR AGENTS; CAPREOMYCIN; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HUMANS; ISONIAZID; KANAMYCIN; MALE; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; RIFAMPIN; SALVAGE THERAPY; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84901609343     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12335     Document Type: Article

References (31)

1. Mukherjee JS, Rich ML, Socci AR et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-81.
2. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008 (WHO/HTM/TB/2008.402). Geneva: WHO, 2008.
3. Rich ML, Socci AR, Mitnick CD et al. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis 2006; 10: 290-6.
4. Shin S, Furin J, Bayona J, Mate K, Kim JY, Farmer P. Community-based treatment of multidrug-resistant tuberculosis in Lima, Peru: 7 years of experience. Soc Sci Med 2004; 59: 1529-39.
5. Mitnick CD, Shin SS, Seung KJ et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-74.
6. Palacios E, Guerra D, Llaro K, Chalco K, Sapag R, Furin J. The role of the nurse in the community-based treatment of multidrug-resistant tuberculosis (MDR-TB). Int J Tuberc Lung Dis 2003; 7: 343-6.
7. Orenstein EW, Basu S, Shah NS et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-61.
8. Holtz TH, Sternberg M, Kammerer S et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006; 144: 650-9.
9. Mitnick C, Bayona J, Palacios E et al. Community-based therapy for multidrug-resistant tuberculosis in Lima Peru. N Engl J Med 2003; 348: 119-28.
10. Saravia JC, Appleton SC, Rich ML, Sarria M, Bayona J, Becerra MC. Retreatment management strategies when first-line tuberculosis therapy fails. Int J Tuberc Lung Dis 2005; 9: 421-9.
11. Chavez Pachas AM, Blank R, Smith Fawzi MC, Bayona J, Becerra MC, Mitnick CD. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Ciudad, Peru. Int J Tuberc Lung Dis 2004; 8: 52-8.
12. Becerra M, Freeman J, Bayona J et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000; 4: 108-14.
13. Shin SS, Yagui M, Ascencios L et al. Scale-up of multidrug-resistant tuberculosis laboratory services Peru. Emerg Infect Dis 2008; 14: 701-8.
14. TCTA International standards for tuberculosis care (ISTC). The Hague: Tuberculosis Coalition for Technical Assistance, 2006.
15. Blaya JA, Shin SS, Yagui MJ et al. A web-based laboratory information system to improve quality of care of tuberculosis patients in Peru: functional requirements, implementation and usage statistics. BMC Med Inform Decis Mak 2007; 7: 33.
16. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3: 432-42.
17. Tsukamura M, Mizuno S. Cross-resistant relationships among the aminoglucoside antibiotics in Mycobacterium tuberculosis. J Gen Microbiol 1975; 88: 269-74.
18. McClatchy JK, Kanes W, Davidson PT, Moulding TS. Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin. Tubercle 1977; 58: 29-34.
19. Bastian I, Colebunders R. Treatment and prevention of multidrug-resistant tuberculosis. Drugs 1999; 58: 633-61.
20. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 2012; 7: e39754.
21. Wise R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J 1999; 14: 221-9.
22. Leone M, Albanese J, Sampol-Manos E et al. Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia. Antimicrob Agents Chemother 2004; 48: 638-40.
23. Capitano B, Mattoes HM, Shore E et al. Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults. Chest 2004; 125: 965-73.
24. Yew WW, Chan CK, Leung CC et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124: 1476-81.
25. Sirgel FA, Botha FJ, Parkin DP et al. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156(3 Pt 1): 901-5.
26. Sirgel FA, Donald PR, Odhiambo J et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000; 45: 859-70.
27. Johnson JL, Hadad DJ, Boom WH et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10: 605-12.
28. Van Deun A, Maug AK, Salim MA et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-92.
29. Ahuja SD, Ashkin D, Avendano M et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9, 153 patients. PLoS Med 2012; 9: e1001300.
30. Kempker RR, Vashakidze S, Solomonia N, Dzidzikashvili N, Blumberg HM. Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis 2012; 12: 157-66.
31. Lee M, Lee J, Carroll MW et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012; 367: 1508-18.